Navigation Links
Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
Date:7/14/2009

TAMPA, Fla., July 14 /PRNewswire/ -- Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell therapy.

QI is currently sponsoring and conducting an FDA-authorized Phase I/II clinical trial testing the safety and efficacy of its immunotherapy on 27 Stage IV breast cancer patients who have failed conventional therapy. According to Mr. Chuck Broes, CEO of QI, "This achievement marks a significant milestone in the life cycle of our company, and we look forward with great hope and commitment as we aspire to a successful trial outcome."

The clinical trials involve the use of dendritic cell therapy using the oncofetal antigen ("OFA"), or iLRP -- immature Laminin Receptor Protein, as a cancer antigen (a protein found on cancer cells that can be targeted by the body's own immune system) found in many tumor cell lines or fetal tissue, but absent on normal, healthy tissue. QI believes that the OFA antigen can serve as a unique, valuable and promising antigen for individualized breast cancer immunotherapy.

Centered in Mobile, AL, QI's clinical trial is designed around the use of QI's proprietary dendritic cell therapy, which employs OFA to recruit the patient's own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient's own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient's T-cells will locate the OFA found on the patient's cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease.

Abo
'/>"/>

SOURCE Quantum Immunologics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
2. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
3. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
6. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
7. Immunotherapy-Based Provisional Patents Mark Significant Discovery
8. Cord Blood America Sees Significant Positives in President Obamas Lifting of Stem Cell Funding Restrictions
9. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
10. Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
11. iCardiac Reports Significant Revenue Growth and Profitability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Md. , Dec. 24, 2014  United ... today that Medtronic, Inc. (NYSE: MDT ... the U.S. Food and Drug Administration (FDA) for ... implantable drug infusion system (including a newly developed ... (treprostinil) Injection delivered intravenously to patients with ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ... the revenue and share analysis. , Full ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... at the 4th Annual Citi Biotech Day in New York ... parties may access a live audio webcast of the conference ... www.BMRN.com . A replay of the call will be ...
... March 25 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI), ... sepsis, today announced that the 29th International Symposium ... Belgium from March 24-27, 2009 will feature a ... that will include presentations from six thought leaders ...
... SAN DIEGO, March 25 Aethlon Medical, Inc. ... that supports the advancement of the Aethlon Hemopurifier(R) ... cure rates. The Hemopurifier(R) is a first-in-class medical ... infectious disease through real-time therapeutic filtration of infectious ...
Cached Biology Technology:BioMarin to Present at the 4th Annual Citi Biotech Day 2Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin 2Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates 2Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates 3Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates 4Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates 5
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Boulders deposited by an ancient glacier that once covered the ... provided more evidence of the extraordinary power and reach of ... Ocean current system that could happen again and continues to ... has found geochemical clues near the summit of Mauna Kea ...
... August 4, 2010 Researchers at the Hebrew University ... the first time a gene associated with susceptibility to ... a significant step toward better understanding and treating of ... problem, afflicting approximately 20% of adults. Some individuals ...
... PITTSBURGHCarnegie Mellon University,s Yoed Rabin has received three ... of Health (NIH) to develop biothermal technology for ... Cryopreservation is the preservation of tissues and organs ... transplantation and regenerative medicine, whereas cryosurgery is the ...
Cached Biology News:Ancient Hawaiian glaciers reveal clues to global climate impacts 2Ancient Hawaiian glaciers reveal clues to global climate impacts 3Hebrew University researchers identify gene related to chronic pain 2Carnegie Mellon's Yoed Rabin receives grants 2
Request Info...
... service provides the premium quality siRNAs you ... siRNAs can be readily ordered online by ... or by providing the sense and antisense ... Validated and Silencer Pre-designed siRNAs, which are ...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: